JE Rossouw, RL Prentice, JAE Manson, LL Wu, … - Jama, 2007 - Am Med Assoc You are seeing this message because your Web browser does not support basic Web
standards. Find out more about why this message is appearing and what you can do
to make your experience on this site better. ... Add to CiteULike Add to ... Cited by 470 - Related articles - BL Direct - All 9 versions
E Barrett-Connor, D Grady, A Sashegyi, PW … - Jama, 2002 - Am Med Assoc You are seeing this message because your Web browser does not support basic Web
standards. Find out more about why this message is appearing and what you can do
to make your experience on this site better. ... Context Raloxifene, a ... Cited by 434 - Related articles - BL Direct - All 8 versions
- ►uvm.edu [PDF] F Grodstein, TB Clarkson, JAE Manson - The New England journal of medicine, 2003 - nejm.highwire.org Recent findings from clinical trials examining the relation between
postmenopausal hormone therapy and coronary heart disease 1 , 2 have appeared to
be widely divergent from the results of earlier observational studies. In ... Cited by 259 - Related articles - BL Direct - All 6 versions
LL Humphrey, BKS Chan, HC Sox - Annals of internal medicine, 2002 - Am Coll Physicians Data Sources: MEDLINE and Cochrane databases were searched for all primary
prevention studies reporting CVD or CAD incidence, mortality, or both in
association with HRT; reference lists, letters, editorials, and reviews ... Cited by 235 - Related articles - BL Direct - All 4 versions
- ►eurekalert.org [PDF] SW Fletcher, GA Colditz - Jama, 2002 - Am Med Assoc Now, the surprising results of the Women's Health Initiative (WHI) are reported
in this issue of THE JOURNAL. 14 The WHI is the first randomized primary
prevention trial of postmenopausal hormones, and the part of the study that ... Cited by 215 - Related articles - BL Direct - All 16 versions
S Units, D Imaging, P Prevention, A … - Cerebrovascular Diseases, 2003 - pt.wkhealth.com For the European Stroke Initiative (EUSI) Executive Committee: Werner Hacke,
Heidelberg, Germany; Markku Kaste, Helsinki, Finland; Julien Bogousslavsky,
Lausanne, Switzerland; Michael Brainin, Maria Gugging, Austria; Angel ... Cited by 163 - Related articles - All 5 versions
E Vittinghoff, D Glidden, SC Shiboski, CE …, 2005 - books.google.com Eric Vittinghoff David V. Glidden Department of Epidemiology and Biostatistics
Department of Epidemiology and Biostatistics University of California University
of California San Francisco, CA 94143 San Francisco, CA 94143 USA USA eric ... Cited by 156 - Related articles - All 4 versions
- ►ahajournals.org A Decensi, U Omodei, C Robertson, B Bonanni … - Circulation, 2002 - Am Heart Assoc Methods and Results— A total of 189 postmenopausal women were randomized to 50
µg/d transdermal E2 and 100 mg BID of the retinoid fenretinide (n=45), 50 µg/d
transdermal E2 and placebo (n=49), 0.625 mg/d oral CEE and 100 mg BID ... Cited by 125 - Related articles - BL Direct - All 10 versions
- ►ahajournals.org DM Herrington, E Vittinghoff, TD Howard, DA … - Arteriosclerosis, thrombosis, and vascular biology, 2002 - Am Heart Assoc Abstract— Oral contraceptive use in women with factor V Leiden is associated
with increased rates of venous thromboembolic events (VTEs). However, the
effects of hormone replacement therapy (HRT) in postmenopausal women with ... Cited by 122 - Related articles - BL Direct - All 9 versions
F Naftolin, HS Taylor, R Karas, E Brinton, … - Fertility and sterility, 2004 - Elsevier The decision of whether to begin hormone therapy (HT) and for how long was,
until recently, relatively easy for the symptomatic, healthy, newly
postmenopausal woman and her caregivers. In addition to relief from ... Cited by 99 - Related articles - All 8 versions
